Related Experiment Video
Updated: May 29, 2026
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Diagnostic markers for glioblastoma
C S Jung1, A W Unterberg, C Hartmann
1Department of Neurosurgery, Institute of Pathology, Ruprecht-Karls-University Heidelberg and Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Germany. carla.jung@med.uni-heidelberg.de
Abstract:
Glioblastoma (GBM) is the most malignant form of cerebral gliomas, and despite distinct progress in surgical resection, radiation and chemotherapy, the prognosis of patients with GBM is still very poor. In the past decades knowledge of genomics and proteomics and of diagnostic, prognostic, predictive and pharmakodynamic markers measured in cerebrospinal-fluid (CSF), serum, or tumor tissue biomarkers has improved. This review briefly compiles our concepts on diagnostic markers for GBM, focusing on the latest developments.
